Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Imperial College, London, UK.
Eur J Heart Fail. 2020 Apr;22(4):618-628. doi: 10.1002/ejhf.1732. Epub 2020 Feb 10.
In five large-scale trials involving >40 000 patients, sodium-glucose cotransporter 2 (SGLT2) inhibitors decreased the risk of serious heart failure events by 25-40%. This effect cannot be explained by control of hyperglycaemia, since it is not observed with antidiabetic drugs with greater glucose-lowering effects. It cannot be attributed to ketogenesis, since it is not causally linked to ketone body production, and the benefit is not enhanced in patients with diabetes. The effect cannot be ascribed to a natriuretic action, since SGLT2 inhibitors decrease natriuretic peptides only modestly, and they reduce cardiovascular death, a benefit that diuretics do not possess. Although SGLT2 inhibitors increase red blood cell mass, enhanced erythropoiesis does not favourably influence the course of heart failure. By contrast, experimental studies suggest that SGLT2 inhibitors may reduce intracellular sodium, thereby preventing oxidative stress and cardiomyocyte death. Additionally, SGLT2 inhibitors induce a transcriptional paradigm that mimics nutrient and oxygen deprivation, which includes activation of adenosine monophosphate-activated protein kinase, sirtuin-1, and/or hypoxia-inducible factors-1α/2α. The interplay of these mediators stimulates autophagy, a lysosomally-mediated degradative pathway that maintains cellular homeostasis. Autophagy-mediated clearance of damaged organelles reduces inflammasome activation, thus mitigating cardiomyocyte dysfunction and coronary microvascular injury. Interestingly, the action of hypoxia-inducible factors-1α/2α to both stimulate erythropoietin and induce autophagy may explain why erythrocytosis is strongly correlated with the reduction in heart failure events. Therefore, the benefits of SGLT2 inhibitors on heart failure may be mediated by a direct cardioprotective action related to modulation of pathways responsible for cardiomyocyte homeostasis.
在五项涉及超过 40000 名患者的大型试验中,钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂使严重心力衰竭事件的风险降低了 25-40%。这种作用不能用控制高血糖来解释,因为它与降血糖作用更强的糖尿病药物无关。它不能归因于酮生成,因为它与酮体产生没有因果关系,并且在糖尿病患者中,益处不会增强。这种作用不能归因于利钠作用,因为 SGLT2 抑制剂仅适度降低利钠肽,并且它们降低心血管死亡,利尿剂没有这种益处。尽管 SGLT2 抑制剂增加了红细胞量,但增强的红细胞生成不会对心力衰竭的病程产生有利影响。相比之下,实验研究表明,SGLT2 抑制剂可能减少细胞内钠,从而防止氧化应激和心肌细胞死亡。此外,SGLT2 抑制剂诱导一种模拟营养和氧气剥夺的转录范例,包括激活单磷酸腺苷激活的蛋白激酶、Sirtuin-1 和/或缺氧诱导因子-1α/2α。这些介质的相互作用刺激自噬,这是一种溶酶体介导的降解途径,可维持细胞内稳态。自噬介导的受损细胞器清除减少了炎症小体的激活,从而减轻了心肌细胞功能障碍和冠状动脉微血管损伤。有趣的是,缺氧诱导因子-1α/2α 的作用是刺激促红细胞生成素和诱导自噬,这可能解释为什么红细胞增多与心力衰竭事件减少密切相关。因此,SGLT2 抑制剂对心力衰竭的益处可能通过与调节负责心肌细胞内稳态的途径相关的直接心脏保护作用来介导。